Acute refractory hyperkalaemia and fatal cardiac arrest related to administration of liposomal amphotericin B

Netherlands Journal of Medicine

Volumn 66, Issue 10, 2008, Pages 433-437

  Groot, O A ^a   Trof, R J ^a,b   Girbes, A R ^a   Swart, N L ^a   Beishuizen, A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Cardiac arrest; Fungal infection; Hyperkalaemia; Liposomal arnphotericin B

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; VORICONAZOLE;

ABSIDIA; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CASE REPORT; DEFIBRILLATION; DRUG FATALITY; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; HYPERKALEMIA; INTENSIVE CARE; LIPOSOMAL DELIVERY; LUNG ASPERGILLOSIS; LUNG LAVAGE; MALE; MYCOSIS; PLEURA EFFUSION; POTASSIUM BLOOD LEVEL; RESPIRATORY FAILURE;

ABSIDIA; ADULT; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; FATAL OUTCOME; HEART ARREST; HUMANS; HYPERKALEMIA; LEUKEMIA, MYELOID, ACUTE; MALE; MUCORMYCOSIS;

EID: 56749109790     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Trof RJ, Beishuizen A, Debets-Ossenkop YJ, Girbes AR, Groeneveld AB. Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med. 2007;33:1694-703.
2. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6:154-64.
3. Craven PC, Gremillion DH. Risk factors of ventricular fibrillation during rapid amphotericin B infusion. Antimicrob Agents Chemother. 1985;27:868-71.
4. Burke D, Lal R, Finkel KW, Samuels I, Foringer JR. Acute arnphotericin B overdose. Ann Pharmacother. 2006;40:2254-9.
5. Clearly JD, Hayman J, Sherwood J, Lasala GP, Piazza-Hepp. Amphotericin B overdose in pediatric patients with associated cardiac arrest. Ann Pharmacother. 1993;27:715-9.
6. Barcia JP. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B. Pharmacotherapy. 1998;18:874-6.
7. Keim GR Jr, Poutsiaka JW, Kirpan J, Keysser CH. Amphotericin B methyl ester hydrochloride and amphotericin B: comparative acute toxicity. Science. 1973;179:584-5.
8. Butler WT, Bennet JE, Hill GJ. Electrocardiographic and electrolyte abnormalities caused by amphotericin B in dog and man. Proc Soc Exp Biol Med. 1964;116:857-63.
9. Cutaia M, Bullard SR, Rudio K, Rounds S. Characteristics of amphotericin B induced endothelial cell injury. J Lab Clin Med. 1993;121:244-56.
10. Ellis ME, al-Hokail AA, Clink HM, et al. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother. 1992;36:172-9.
11. Oldfield EC, Garst PD, Hostettler C, White M, Samuelson D. Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob Agents Chemother. 1990;34:1402-6.
12. Bowler WA, Weiss PJ, Hill HE, et al. Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function. Antimicrob Agents Chemother. 1992;36:2542-3.
13. Cruz JM, Peacock JE Jr, Loomer L, et al. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med. 1992;93:123-30.
14. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994;38:713-8.
15. Trof RJ, Brouwer RM. Life threatening hyperkalemia: the value of the electrocardiogram. Ned Tijdschr Geneeskd. 2004;148:969-75.
16. Gales MA, Gales BJ. Rapid infusion of amphotericin B in dextrose. Ann Pharmacother. 1995;29:523-9.
17. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322:579-82.
18. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36:943-51.
19. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother. 2001;45:922-6.